Navigation Links
Genedata Screener 11 with Compound Combination Screening and Collaboration in the Cloud Announced at Bio-IT World 2013
Date:4/9/2013

Boston, MA (PRWEB) April 09, 2013

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of Genedata Screener® 11, a single-platform screening data analysis system with built-in business logic for standardizing and automating screening workflows. The new Genedata Screener now supports compound combination screens to analyze compound synergy effects as well as high throughput flow cytometry including cell sub-population analysis. Integrating with any plate-based instrument, Genedata Screener supports High, Medium and Low Throughput Screens, High Content Screening (HCS), Ion Channel Screening, Label-free (including thermal shift), and other assay technologies. Now, it also can be used in the cloud to enable pharma-CRO collaboration on the same analysis platform. Genedata Screener 11 will be demonstrated April 9 -11 at the Bio-IT World Conference & Expo (World Trade Center; Booth #228).

Realizing the Promise of Compound Combination Screening
Compound Combination Screening holds the promise of lowering costs for drug discovery while delivering significantly improved drug therapies for illnesses such as cancer, diabetes, and infectious diseases. Today’s instrumentation enables high-throughput Compound Combination Screening experiments measuring, for example, 200 or more combinations across several cell lines. Data analysis, however, for combination experiments remains a major bottleneck as the specifics of combination screening are not fully supported by current screening data analysis systems. The Genedata Screener Compound Synergy Extension removes this bottleneck to enable full realization of the experimental capacity. Compound Synergy Extension can easily be added to an existing Genedata Screener installation, which:

  • Eliminates manual data processing of compound synergy data
  • Imports information for multiple compounds per well from files or database systems
  • Fits mono-therapeutic Dose Response Curves
  • Calculates Synergy Scores using the Loewe and Highest Single Agent models
  • Visualizes combination effects in heat maps (e.g. for measured, modeled and excess activity)

New Applications for Single-Cell Analysis
Genedata Screener 11 also features an enhanced Cell Population Extension for improved support of high throughput flow cytometry, cell cycle and similar experiments that define and display cell sub-populations. In a single view, researchers can define, manage, and display cell sub-populations and use cell sub-populations as input for cell-to-well data aggregation. These capabilities streamline processing of cell-based experiments and enable corporate-wide management of single-cell data, at an unprecedented scale.

Collaboration in the Cloud
Enabling new levels of collaborative research and screening data analysis, Genedata Screener 11 features advanced support for encrypted data transmission and authentication. Fully cloud-compliant, Genedata Screener 11 standardizes data analysis across different organizations and multiple sites. With the Genedata Screener server in the cloud, users run their clients in the local environment: while data transfer to and from the cloud is determined by the bandwidth of the network connection, Genedata Screener data processing speed and unique interactive capabilities persist.

“Genedata Screener 11 will unleash new opportunities in lead optimization and target validation by giving pharmaceutical and biotechnology researchers a standardized platform on which they can efficiently visualize and explore compound combinations at unprecedented processing speed and with unsurpassed result quality,” said Dr. Othmar Pfannes, CEO of Genedata. “The ongoing innovation we are able to consistently deliver with each version of Genedata Screener is a result of our partnerships with industry leaders and our significant investments in and commitment to Genedata R&D.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10600839.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
2. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
3. Ono Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry
4. Genedata Biologics 3.0 Boosts Efficiency Through Standardization
5. Genedata Screener Adopted for all Plate-based Screening by Major Pharmas
6. Genedata Screener for HCS Advances Phenotypic Screening
7. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
8. Genedata Screener to Present at 10th Annual Ion Channel Retreat
9. Transcreener Assays Highlighted for Challenging Microbial, Cancer and Epigenetic Drug Targets at SLAS 2013
10. Risk Assessment and Mitigation in Phase I Trials in High Risk Compounds: A Continuously Developing Process, new life science webinar hosted by Xtalks
11. Love triumphs over hate to make exotic new compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):